Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02467231 · ClinicalTrials.gov registry record

Ovarian Reserve After Cancer: Longitudinal Effects

A clinical trial of Premature Ovarian Failure and Effects of Chemotherapy, sponsored by University of Pennsylvania.

Active
Registry status
196
Enrollment target
1
Study location

NCT02467231 is a study of Premature Ovarian Failure and Effects of Chemotherapy that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 196 participants, above the 25-participant average among 3 other Premature Ovarian Failure trials with a reported enrollment target (684% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02467231, a study of Premature Ovarian Failure and Effects of Chemotherapy, is active but no longer recruiting, sponsored by University of Pennsylvania.

ACTIVE NOT RECRUITING
Registry status
196 participants
Enrollment target
1
Study location

Study Summary

Women of reproductive age who will receive treatment for cancer that includes chemotherapy may participate in a study measuring ovarian function over time. Eligible women are asked to complete a questionnaire, a menstrual diary, a brief physical examination, an ultrasound, and a blood test before, during and after cancer treatment.

Study Locations (1)

Pennsylvania

  • University of Pennsylvania, Reproductive Research Unit - Philadelphia

Trial Details

FieldValue
Enrollment Target 196 participants
Start Date 2009-02
Est. Completion 2028-12

Sponsor

University of Pennsylvania

1,423 total trials

What the Registry Record Tells You About NCT02467231

The ClinicalTrials.gov registry entry for NCT02467231 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 25-participant average among 3 other Premature Ovarian Failure trials with a reported enrollment target (684% higher). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Premature Ovarian Failure appearing as the primary indexed condition, and to 0 interventions.

NCT02467231 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT02467231 about?

NCT02467231 is a clinical study titled "Ovarian Reserve After Cancer: Longitudinal Effects". Women of reproductive age who will receive treatment for cancer that includes chemotherapy may participate in a study measuring ovarian function over time. Eligible women are asked to complete a questionnaire, a menstrual diary, a brief physical examination, an ultrasound, and a blood test before, d...

What is the current status of trial NCT02467231?

This trial is currently active not recruiting. The enrollment target is 196 participants. The study started on 2009-02. Estimated completion is 2028-12.

What conditions does trial NCT02467231 study?

This clinical trial studies the following conditions: Premature Ovarian Failure, Effects of Chemotherapy.

Who is sponsoring clinical trial NCT02467231?

This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02467231 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Premature Ovarian Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.